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Longitudinal changes in glucocorticoid receptor exon 1F
methylation and psychopathology after military deployment
RR Schür1, MP Boks1, BPF Rutten2, NP Daskalakis3,4, L de Nijs2, M van Zuiden5, A Kavelaars6, CJ Heijnen6, M Joëls7,8, RS Kahn1,
E Geuze1,9, E Vermetten9,10 and CH Vinkers1
Several cross-sectional studies have demonstrated the relevance of DNA methylation of the glucocorticoid receptor exon 1F region
(GR-1F) for trauma-related psychopathology. We conducted a longitudinal study to examine GR-1F methylation changes over time
in relation to trauma exposure and the development of post-deployment psychopathology. GR-1F methylation (52 loci) was
quantified using pyrosequencing in whole blood of 92 military men 1 month before and 6 months after a 4-month deployment
period to Afghanistan. GR-1F methylation overall (mean methylation and the number of methylated loci) and functional
methylation (methylation at loci associated with GR exon 1F expression) measures were examined. We first investigated the effect
of exposure to potentially traumatic events during deployment on these measures. Subsequently, changes in GR-1F methylation
were related to changes in mental health problems (total Symptom Checklist-90 score) and posttraumatic stress disorder (PTSD)
symptoms (Self-Report Inventory for PTSD). Trauma exposure during deployment was associated with an increase in all methylation
measures, but development of mental health problems 6 months after deployment was only significantly associated with an
increased functional methylation. Emergence of post-deployment PTSD symptoms was not related to increased functional
methylation over time. Pre-deployment methylation levels did not predict post-deployment psychopathology. To our knowledge,
this is the first study to prospectively demonstrate trauma-related increases in GR-1F methylation, and it shows that only increases
at specific functionally relevant sites predispose for post-deployment psychopathology.
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INTRODUCTION
Exposure to traumatic stress is a major risk factor for a wide range
of psychiatric disorders, including posttraumatic stress disorder
(PTSD) and major depressive disorder (MDD).1 The hypothalamus–
pituitary–adrenal (HPA) axis is crucial for an adequate response to
a stressful environment. The glucocorticoid receptor (GR) deter-
mines negative feedback on the HPA axis, and impaired GR
functionality has been proposed as a potential pathophysiological
mechanism underlying both PTSD and MDD.2
Over a decade ago, Weaver et al.3 demonstrated that DNA
cytosine methylation of the GR exon 17 promoter in the
hippocampus of rats remains elevated after early life stress and
leads to decreased GR expression and increased adult HPA axis
activity. This methylation effect was particularly pronounced at a
nerve growth factor-inducible protein A (NGFI-A) transcription
factor binding site. McGowan et al.4 translated these findings to
humans, showing elevated methylation in the GR exon 1F region
(GR-1F) in the hippocampus of suicide victims with a childhood
abuse history compared with nonabused suicide victims and
controls. Following these seminal reports, the number of studies
examining GR-1F methylation in relation to traumatic stress
and stress-related psychiatric disorders has steadily increased
(for reviews see refs 5–7). Of note, all of these studies
examined peripheral tissues to assess GR-1F methylation and
significant findings were not limited to NGFI-A-binding sites. In
humans, both pre- and postnatal stress have consistently been
linked to increased GR-1F methylation in most,
5 but not all
studies.8 In addition, decreased GR-1F methylation has been
found in patients with MDD,9 whereas both increased10 and
decreased11 GR-1F methylation were reported in patients with
PTSD compared with the controls. These studies all employed a
cross-sectional design, which precludes conclusions about caus-
ality. As a result, it is still unknown whether GR-1F methylation
changes as psychopathology emerges and/or whether it
represents a pre-existing vulnerability factor predicting the
development of psychopathology.
We therefore quantified GR-1F methylation levels in peripheral
blood cells of Dutch military personnel before and after deploy-
ment to Afghanistan. In line with the accumulating evidence (for
an overview see Daskalakis et al.5), we hypothesized that trauma
exposure during deployment would increase GR-1F methylation.
In addition, we wanted to explore the direction of GR-1F
methylation change in relation to emerging psychopathology
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symptoms after deployment, as previous evidence is equivocal.5
As reported in a previous study,11 we expected methylation
changes associated with changes in GR exon 1F expression to be
most informative of change in psychopathology symptoms.
Furthermore, we investigated the predictive value of pre-
deployment GR-1F methylation for the development of post-
deployment psychopathology symptoms. Finally, we explored the
association between GR-1F methylation and six functional
haplotypes of the GR gene (NR3C1), which were previously




The present study was part of a large longitudinal cohort of Dutch military
personnel that were deployed to Afghanistan (n= 1032), as part of the
International Security Assistance Force, between 2005 and 2008 (for details
on procedures see refs 13,14). Among their duties were searching and
clearing of buildings, combat patrols, transport across enemy territory and
demining operations. The individuals were exposed to potentially
traumatic events such as armed combat, combat casualties and enemy
fire. Individuals were assessed (questionnaires were administered and
blood samples were drawn) 1 month before, and 1 and 6 months after a 4-
month period of deployment. This study examined methylation measures
prior to and 6 months after deployment, as psychopathology levels were
highest 6 months after deployment.13 To maximize power,15 three
subgroups of approximately equal size were selected from this cohort
(N= 92) based on exposure to potentially traumatic events during
deployment (high or low) and post-deployment psychopathology (high
or low, only in group with high trauma exposure).16 The study was
approved by the Institutional Review Board of the University Medical
Center Utrecht (UMCU) and both oral and written informed consent was
obtained from all participants.
Mental health problems were assessed with the validated Dutch version
of the Symptom Checklist-90 (SCL-90), which includes the total score of
eight symptom dimensions: agoraphobia, anxiety, depression, somatiza-
tion, cognitive performance deficits, mistrust and interpersonal sensitivity,
hostility and sleep difficulties.17 PTSD symptoms were measured using the
Self-Report Inventory for PTSD (SRIP).18 Changes in SCL-90 and SRIP scores
were significantly correlated (ρ= 0.52). A 19-item self-report deployment
experiences checklist was used to assess traumatic stress exposure during
deployment, such as direct combat stressors.13 For childhood trauma, the
Early Trauma Inventory-Self Report was used, which includes emotional,
physical and sexual abuse.19 For prediction of the development of
psychopathology after deployment, individuals were divided into groups
with low or high symptom levels based on previously defined cutoff scores
of 124 for total SCL-90 and 38 for the SRIP.14,17,20 This SCL-90 cutoff score
delineates individuals in the general population exceeding average
symptoms.21 The SRIP cutoff score14 is in the range with the best
sensitivity and specificity for PTSD classification according to the DSM-IV
(in a general population).22
Biological measures
Methylation was quantified in 52 CpGs in and adjacent to the 1F region
(see Figure 1, numbering in accordance with Daskalakis et al.5). The NGFI-
A-binding sites in this region (CpG numbers: 17, 18, 21–26, 35–37, 42, 43)
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Figure 1. The glucocorticoid receptor exon 1F region (GR-1F) in NR3C1. (a) All 52 5′-C–phosphate–G-3′ sites (CpGs) where methylation was
measured in the present study are numbered (red: CpGs where change in methylation was associated with GR exon 1F expression change).
Lowercase letters mark the promoter region, uppercase letters the GR-1F exon. Black-lined boxes represent canonical (solid) and non-
canonical (dashed) NGFI-A binding sites, after McGowan et al.4 (b) NR3C1 (Chromosome 5: 142 657 496–142 815 077) from the 5′ (left) to 3′
(right) untranslated region. Boxes on the horizontal black line represent exons (gray: non-coding, green: coding sequence). The light gray box
indicates a CpG island in the proximal promoter region (from 1D to 1H). (c) Six common and functional haplotypes constituted by six SNPs
(rs10052957, rs10482605, rs6189, rs6195, rs41423247 and rs6198) and their frequencies in the present study. Red letters represent the minor
alleles. For a scaled representation of exons 2 through 9 in relation to the first exons, see Sinclair et al.23
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Whole-blood EDTA samples were collected 1 month before and
6 months after deployment. Standard salting procedures were used to
extract DNA. Subsequently, DNA concentration and integrity were
determined using riboGreen (Thermo Fisher Scientific, Waltham, MA,
USA) and BioAnalyser (Agilent Technologies, Santa Clara, CA, USA),
respectively.
GR-1F methylation data were available for 92 individuals. For methyla-
tion analysis (EpigenDx, Hopkinton, MA, USA24–26), DNA was denatured
using 3 N NaOH followed by 30- min incubation at 42 °C. Bisulfite salt
solution was added to the DNA and incubated for 14 h at 50 °C. Bisulfite-
treated DNA was purified using Zymogen DNA columns and eluted in 20 μl
T1E0.2 (pH 8) and 1 μl was used for each PCR. PCR was performed using
5 ng of genomic DNA and 0.2 μM of each primer. The final PCR product was
purified using Sepharose beads (GE Healthcare Life Sciences, Pittsburgh,
PA, USA) and the Pyrosequencing Vacuum Prep Tool (Qiagen, Valencia, CA,
USA) as recommended by the manufacturer. Purified PCR product was
sequenced using 0.2 μM pyrosequencing primer on the Pyrosequencing
PSQ96 HS System (Qiagen) following the manufacturer’s instructions. The
percentage of methylation at each locus was determined by looking at the
CpG site as an artificial C/T SNP using QCpG software (Qiagen), where C%
equals %methylation as calculated by the equation below:
C% ¼ RLU Cpeakð Þ=RLU Cpeakþ Tpeakð Þ:
All samples resulted in good pyrosequencing signals and good quality data
(for assays, sensitivity, coefficients of variance, numbers of CpG sites and
chromosomal regions targeted by the primers, see Supplementary Table
S1 in the online data supplement). As GR-1F methylation levels are
generally low,27,28 two measures of overall GR-1F methylation were
examined: mean methylation across all CpGs and the number of
methylated loci (the number of CpGs with 40% methylation). In addition,
to optimally investigate the functional dynamics of methylation, we
focused on those CpGs where we observed that longitudinal changes in
methylation were significantly related to change in GR exon 1F mRNA
expression (for the latter see below), defined as functional methylation. In
exploratory analyses, we examined DNA methylation at NGFI-A-
binding sites.
GR exon 1F expression data were available for 75 individuals, as RNA
quality was not sufficient in 17 individuals. Pre- and post-deployment RNA
from peripheral blood mononuclear cells (PBMCs) was isolated with TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. RNA concentrations were determined using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). One μg of total RNA was converted into first-strand cDNA with oligo
(dT) primers using RevertAid First Strand cDNA Synthesis Kit (Thermo
Fisher Scientific, Waltham, MA, USA) as described by the manufacturer.
qPCR assays were carried out in duplicate in a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) with specific primers
(see Supplementary Table S3 in the online data supplement) and SensiMix
SYBR Hi-ROX (Bioline Reagents, London, UK). For normalization of mRNA
expression, RefFinder (OMICtools, Sotteville-Les-Rouen, France) was used
to find the most stable reference gene among PPIB, YWHAZ, RPL13a and
RPL37a. The relative abundance of mRNAs was standardized with RPL13a
mRNA as the invariant control.
In line with the finding that lower GR-1F methylation is associated with
dampening of the cortisol response through higher GR-mediated negative
feedback,3 we hypothesized GR-1F methylation to be negatively associated
to GR sensitivity. Data on GR-binding capacity of PBMCs were available for
47 individuals, as these were acquired several years earlier from a largely
overlapping cohort.20 As previously described,20 GR-binding capacity was
quantified using a modification of the whole-cell single point-binding
assay described by Yehuda et al.29 Using this protocol, specific binding at
100 nM 3H-dexamethasone gave a reliable Bmax, which was determined
with a classical binding assay with 3-200 nM 3H-dexamethasone in the
absence or presence of an excess of unlabeled dexamethasone
(r2 = 0.92).20 In short, Ficoll-Paque (Pharmacia and Upjohn, Uppsala,
Sweden) was used to isolate PBMCs from heparinized whole blood, and
107 cells were frozen in RPMI-1640 (Gibco, Grand Island, NY, USA) in
addition of 10% fetal calf serum (FCS) (Gibco) and 20% DMSO. Samples of
every single individual were analyzed simultaneously. Cells were thawed,
and subsequently washed twice in RPMI-1640 and incubated for 30 min at
37 °C. Again, cells were washed twice, after which they were resuspended
in assay buffer (RPMI- 1640 with 10% FCS) and incubated in duplicate with
100 nM 3H-dexamethasone (Amersham, Buckinghamshire, UK) in the
absence or presence of excess unlabeled dexamethasone (Sigma-Aldrich,
Steinheim, Germany). After 60 min incubation at 37 °C, cells were washed
twice in ice cold assay buffer followed by density centrifugation over Ficoll
hypaque, separating cell-bound label from free label. Liquid scintillation
analysis was used to analyze cell-bound radioactivity. In two simulta-
neously processed samples the number of cells was counted.
To examine the effect of genetic variation in the GR gene (NR3C1) on
GR-1F methylation, six SNPs linked to glucocorticoid sensitivity
(rs10052957, rs10482605, rs6189, rs6195, rs41423247 and rs6198)12 were
selected. SNPs were genotyped on the Illumina Human OmniExpress-24
Beadchip array, and genetic data were subjected to quality control (see
Supplementary Table S4 in the online data supplement for quality control
information). SNPs rs10482605, rs6189 and rs41423247 were imputed
using the Haplotype Reference consortium release 1.1. R2 values and
average call rates were40.99 for all three SNPs, whereas allele frequencies
did not deviate from Hardy–Weinberg equilibrium (all P-values 40.05).
Haplotypes were constructed using SNPHAP,30 yielding the following
NR3C1 haplotypes: CTGACA (40%), CTGAGA (22%), TTGAGA (15%), TCGACG
(13%), CTGGCA (4%) and TCAACG (4%)). NR3C1 haplotypes and individual
SNPs from 85 individuals were available.
Statistical analyses
Longitudinal changes in GR-1F methylation around deployment were
analyzed by applying mixed models for repeated measures (MMRM) using
the nlme package31 in R. The relation of changes in GR methylation with
trauma exposure was investigated in a model without adjustment for
symptom outcomes whereas the relation with symptom outcomes was
investigated in a model with adjustment for trauma exposure during
deployment (methylation~methylationpre+trauma during deployment ×
time+change in mental health problems × time, random factor: subject ID).
We only used continuous measures. PTSD symptom scores were log-
transformed to improve the distribution.6 In secondary analyses, NR3C1
haplotypes/SNPs or childhood trauma was added to the model. To
investigate the influence of GR-1F methylation on GR-1F expression and
GR-binding, the latter two measures were used as dependent variables (for
example, expression ~ expressionpre+trauma during deployment × time
+change in methylation × time, random factor: subject ID).
Linear regression models were used to examine the cross-sectional
relations between pre-deployment GR-1F methylation and childhood
trauma or NR3C1 haplotypes/SNPs. Pre- and post-deployment psycho-
pathology symptoms were compared using paired two-tailed t-tests.
Methylation values of one individual were 48 s.ds above the mean
methylation and were excluded from further analyses (resulting in n= 91).
Random effects and residuals of the main MMRM were plotted and
evaluated for heteroscedasticity and did not show further aberrations.
Considering the relatedness and relatively low number of tests, the
significance threshold was set at Po0.05 in primary analyses. However, as
12 NR3C1 haplotypes/SNPs were investigated without prior hypotheses,
the significance threshold in these analyses was set at Po0.0042 (0.05/12).
For prediction, receiver operation curves (ROC) were constructed to
predict a high level of post-deployment mental health problems or PTSD
symptoms with pre-deployment GR-1F methylation. Individuals with a high
level of pre-deployment mental health problems (n=8) or PTSD symptoms
(n=0) were excluded in the respective analyses. Areas under the curve
(AUCs) and corresponding P-values were determined using the verification
package in R.32 Sensitivity, specificity, positive and negative predictive
values were calculated using the Epi package.33
Potential confounding was investigated by analyzing the correlations of
age, body-mass index (BMI), military rank, education, previous number of
deployments and white blood cell counts (including values of neutrophils,
lymphocytes, monocytes, eosinophils and basophils) with methylation
before and after deployment. Moreover, we analyzed the interaction of
these covariates with time in our main models to investigate whether they
affected the relation between our variables of interest (trauma, and change
in psychopathology, GR exon 1F expression and GR-binding) and change in
GR-1F methylation.
To investigate the possible influence of alcohol use, medication and
smoking, we excluded all individuals that changed medication between
baseline and follow-up (n= 18, for types of medication see Supplementary
Table S3 in the online data supplement), as well as individuals with a
changed alcohol use (n = 1) or smoking status (n=6) in sensitivity
analyses.
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RESULTS
Sample characteristics, including information on age, childhood
trauma, number of previous deployments, number of
deployment-related trauma events, BMI, education, rank, mental
health problems and PTSD symptoms are listed in Table 1.
Mean methylation per locus ranged from 0 to 2.60% (see
Supplementary Table S2 in the online data supplement).
Methylation changes per locus were highly correlated, especially
for CpGs 31 to 52 (see Supplementary Figure S1 in the online data
supplement).
Change in GR-1F methylation was associated with change in GR
exon 1F expression at a nominal significance level at the following
17 CpGs: 1, 9, 11, 12, 23, 24, 28, 34, 39, 40, 45–51 (all P-values
o0.05, see Figure 1, as well as Supplementary Table S2 and
Supplementary Figure S2 in the online data supplement). The
mean methylation at these sites constituted our measure of
functional methylation. Changes in our three main methylation
measures (mean methylation, number of methylated sites and
functional methylation) over time were significantly correlated
with a minimal ρ of 0.89. Increases in all three methylation
measures were associated with decreases in GR exon 1F
expression (mean methylation: β=− 0.54, P= 0.011; number of
methylated loci: β=− 0.039, P= 0.001; functional methylation:
β=− 0.526, Po0.001, see Table 2 and Figures 2a and b) and GR-
binding (mean methylation: β=− 463, P= 0.014; number of
methylated loci: β=− 29.9, P= 0.010; functional methylation:
β=− 317, P= 0.016). In exploratory analyses, methylation change
at NGFI-A binding sites was not associated with a change in GR
exon 1F expression (β=− 0.22, P= 0.36) or GR-binding (β=− 413,
P= 0.06) and was therefore not further analyzed.
GR-1F methylation and exposure to potentially traumatic events
Trauma exposure during deployment was significantly associated
with an increase in all three methylation measures (mean
methylation: β= 0.040, P= 0.003; number of methylated loci:
β= 0.75, P= 0.002; functional methylation: β= 0.56, P= 0.002, see
Table 2) and with an increase in methylation at 23 individual CpGs:
2, 4, 8, 9, 17, 19, 20, 22, 28, 31, 32, 34, 35, 39, 40, 45–52 (see
Supplementary Table S2 in the online data supplement).
No significant associations were observed between childhood
trauma and our main methylation measures (change in methyla-
tion over time: all P-values40.54; pre-deployment methylation: all
P-values 40.40).
GR-1F methylation and the development of psychopathology
Although the development of mental health problems was only at
trend level significance associated with an increase in the number
of methylated loci (β= 0.089, P= 0.050) (Figure 2c) and not with
mean methylation (β= 0.004, P= 0.10), it was significantly
associated with an increase in functional methylation (β= 0.010,
P= 0.005) (Table 2 and Figure 2d). Significant associations
between change in mental health problems and methylation
change existed at 14 CpGs (22, 31–35, 39–41, 44, 47, 48, 51, 52).
The development of PTSD symptoms was not associated with
change in any methylation measure (all P-values 40.12, see
Table 2). At a nominal significance level, change in PTSD
Table 1. Sample characteristics (total: n= 91, all male)
Characteristics Mean s.d. Range
Age 27.5 9.3 18–54
Childhood trauma 3.0 2.6 0–11
Number of previous deployments 0.9 1.2 0–5
Number of deployment-related trauma events 5.4 4.2 0–13
BMI 24.4 2.7 18.1–35.8
Education Low Moderate High
42 42 6
Rank Private Corporal Non-commissioned officer (Staff ) officer
45 20 17 8
Pre-deployment Post-deployment t df P
Mean s.d. Range Mean s.d. Range
103.7 17.1 90–209 110.8 23.1 90–204 2.97 87 0.004
26.4 4.0 22–36 31.9 9.9 22–56 4.81 87 0.000006
Abbreviation: BMI, body-mass index. Education: low: some years of high school; moderate: finished high school; high: some years of college or university.
Information about rank and education was missing for one subject.
Table 2. Summaries of the main analyses: associations of change in methylation (mean, number of methylated sites and functional) with trauma







GR exon 1F expression
(n= 75)
GR-binding (n= 47)
β t P β t P β t P β t P β t P
Mean 0.040 3.02 0.003 0.004 1.65 0.10 0.233 1.05 0.30 − 0.543 − 2.63 0.011 − 463 − 2.56 0.014
Number of methylated loci 0.745 3.24 0.002 0.089 1.98 0.050 4.356 1.14 0.26 − 0.039 − 3.41 0.001 − 29.9 − 2.68 0.010
Functional 0.056 3.16 0.002 0.010 2.89 0.005 0.450 1.53 0.13 − 0.526 − 4.02 o 0.001 − 317 −2.51 0.016
Abbreviations: GR, glucocorticoid receptor; PTSD, posttraumatic stress disorder.
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symptoms was associated with methylation change at 9 individual
CpGs (10, 20, 25, 31, 35–37, 44, 51, see Supplementary Table S2 in
the online data supplement).
GR-1F methylation and genetic variation in NR3C1
None of the NR3C1 haplotypes or individual SNPs was significantly
associated with either pre-deployment or prospective changes in
GR-1F methylation measures after correcting for multiple testing
(data not shown). Nevertheless, rs10052957 showed an associa-
tion with prospective methylation changes at a nominal
significance level (TC carriers with CC as reference; mean
methylation: β=− 0.25, P= 0.046; number of methylated loci:
β=− 4.21, P= 0.045; functional methylation: β=− 0.38, P= 0.022).
Confounder and sensitivity analyses
Confounding by age, BMI, military rank, education, previous
number of deployments and white blood cell counts (including
values of neutrophils, lymphocytes, monocytes, eosinophils and
basophils) was highly unlikely as these measures were not
correlated with methylation before or after deployment (P-values
40.05). In addition, cell-type composition was similar before and
after deployment.16 Furthermore, including the interactions of
these covariates with time did not affect the associations between
change in GR-1F methylation with trauma exposure during
deployment, change in mental health problems or PTSD
symptoms, change in GR-1F expression or change in GR-binding.
No individuals used antidepressants at any time point (see
Supplementary Table S5 in the online data supplement). Exclusion
GR-1F expression and methylated loci
Mental health problems and methylated loci Mental health problems and functional methylation
GR-1F expression and functional methylation
Figure 2. Change in mental health problems in relation to (a) the number of methylated loci (n= 88, β= 0.089, P= 0.050) and (b) functional
methylation (n= 88, β= 0.010, P= 0.005), and change in GR exon 1F expression in relation to (c) the number of methylated loci (n= 75,
β=− 0.039, P= 0.001) and (d) functional methylation (n= 75, β=− 0.53, Po0.001). Standardized change indicates that methylation levels after
deployment were adjusted for pre-deployment values.
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of individuals with changed medication, smoking status or alcohol
use status after deployment (total n= 23) strengthened most
associations of GR-1F methylation in the longitudinal analyses (as
indicated by the βs) except for the associations with GR-binding,
which did not remain significant (see Supplementary Table S6 in
the online data supplement).
Prediction of post-deployment psychopathology by
pre-deployment GR-1F methylation
Pre-deployment methylation did not significantly predict a high
level of post-deployment mental health problems (mean methyla-
tion: AUC= 0.51, P= 0.47; number of methylated loci: AUC= 0.54,
P= 0.32; functional methylation: AUC= 0.51, P= 0.47) or PTSD
symptoms (mean methylation: AUC= 0.58, P= 0.11; number of
methylated loci: AUC= 0.56, P= 0.18; functional methylation:
AUC= 0.56, P= 0.17).
DISCUSSION
We examined longitudinal changes in whole-blood GR-1F
methylation from 1 month prior to until 6 months after a 4-
month period of military deployment in relation to deployment-
related trauma and the development of mental health problems
and PTSD symptoms. We found that deployment-related trauma
was associated with an increase in all GR-1F methylation measures.
However, only an increase in GR-1F methylation at loci associated
with GR exon 1F expression (functional methylation) was
significantly related to the development of post-deployment
mental health problems. In contrast, the emergence of PTSD
symptoms was not associated with an increase in functional
methylation over time. Pre-deployment GR-1F methylation did not
predict a high level of psychopathology symptoms after deploy-
ment. Moreover, six functional NR3C1 haplotypes and the six SNPs
constituting these haplotypes were not associated with changes
in GR-1F methylation.
We believe this study provides the first longitudinal evidence in
humans that methylation differences between trauma- and non-
trauma-exposed individuals previously reported in the majority of
cross-sectional studies (see for review Daskalakis et al.5) reflect a
response to traumatic stress exposure. An increase in GR-1F
methylation at functionally relevant sites could result in impaired
negative feedback on the HPA axis,34 leading to increased
vulnerability to psychopathology. The here reported association
between functional GR-1F methylation increase and emerging
mental health problems fits this hypothesis. In contrast, we did not
find any associations between childhood trauma and GR-1F
methylation, whereas most, but not all,8 previous studies found
a positive association (see for review Daskalakis et al.5). Of note,
the fact that elevated GR-1F methylation levels could constitute a
vulnerability factor for the development of psychopathology was
not supported by our prediction models and has not been
investigated in prior studies. Moreover, the only two previous
longitudinal studies on GR-1F methylation do not indicate that
psychotherapeutic interventions influence this hypothesized
pathophysiological mechanism. Perroud et al.35 reported no
change in mean GR-1F methylation in 61 patients with borderline
personality disorder after intensive dialectical behavior therapy.
Yehuda et al.28 showed that pre-treatment GR-1F methylation
levels (sum and number of methylated loci) significantly differed
between responders (n= 8) and non-responders (n= 8) receiving
psychotherapy for PTSD, but did not find a significant methylation
change over time.
In contrast to our study, it was previously observed that
individuals with a high level of post-deployment PTSD symptoms
had increased GR sensitivity36 and GR-binding14,37 prior to
deployment (whereas depressive symptom development was
associated with decreased GR sensitivity36). Moreover, Yehuda
et al.11 found lower GR-1F methylation and evidence for increased
GR sensitivity in PTSD patients compared with trauma-exposed
controls. These opposing directionalities of effects cannot be
ascribed to a difference in pathophysiology between PTSD
symptoms and mental health problems (measured with the
SCL-90), as Yehuda et al.11 found negative associations of GR-1F
methylation with both outcomes, whereas we found positive
associations (not significant for PTSD symptoms). Of note, both
increased and decreased functionality of the GR have been linked
to psychopathology, and Raison and Miller2 previously suggested
that these mechanisms are specific to PTSD and MDD, respec-
tively. However, two recent studies contradict this hypothesis,
showing decreased GR-1F methylation in MDD
9 and increased
GR-1F methylation in PTSD.
10 Moreover, PTSD and MDD often co-
occur which complicates the interpretation of findings. This is
illustrated by the significant correlation (ρ= 0.50) between change
in depressive symptoms (subscale SCL-90) and change in PTSD
symptoms in the present study.
The main strength of the current study is its longitudinal design,
with GR-1F methylation, expression, GR-binding and psychiatric
outcomes assessed before and after military deployment.
Evidence from longitudinal studies is paramount as it is much
less influenced by genetic predispositions and other confounding
factors that may influence both methylation levels and psycho-
pathology than cross-sectional studies. In addition, the present
study investigated the entire GR exon 1F region, allowing
examination of all CpGs in relation to GR exon 1F expression.
This approach highlights that associations between change in
GR-1F methylation and expression are site-specific and present at
17 out of 52 CpGs. Thirteen of these 17 CpGs have previously been
associated with trauma and/or psychopathology (CpG numbers 1,
9, 23, 28, 34, 40 and 45–51, see this review5). Our findings do not
support an important role for NGFI-A binding sites in GR-1F
transcription. This is in line with recent evidence suggesting that
several other transcription factors are important in the GR exon 1F
region.38 Other strengths are the generally healthy cohort at
baseline, the absence of antidepressant use at any time point and
the sensitivity analyses that exclude a confounding effect of
change in any medication, smoking or alcohol use status. Finally,
we explored the associations between NR3C1 haplotypes and
SNPs with GR-1F methylation and did not find any significant
associations with baseline GR-1F methylation, which is in line with
a recent study,39 or with methylation change. This finding
highlights the fact that GR-1F methylation is just one biological
mechanism influencing GR sensitivity, whereas NR3C1 haplotypes
may be independently associated with GR functioning and
psychopathology.12
A possible limitation is the relevance of peripheral blood
methylation to the brain. Several studies suggest that methylation
differences across tissues are substantial,40,41 even though
consistent effects of various methylation quantitative trait loci
are found across tissues.42 However, the effect of trauma,
mediated through stress hormones or cytokines, appears to affect
the epigenome in a wide range of cell and tissue types.7 This is in
line with findings of Tyrka et al.,34 who demonstrated a cross-
sectional relation between trauma-related whole-blood GR-1F
methylation with decreased negative feedback of the HPA axis.
Also, increased GR-1F methylation in peripheral blood cells has
consistently been linked to (early life) adversity.5 The question of
generalizability of methylation patterns across tissues also pertains
to our measurement of GR exon 1F expression and GR-binding in
PBMCs, instead of whole blood.43 Another limitation is our focus
on GR-1F, whereas methylation in other parts of NR3C1 may hold
additional information about the relation between trauma and GR
function.44 In addition, only Dutch Caucasian males were
investigated that limits the generalizability. This may be relevant
as there is evidence for ethnic and sex-specific differences in
cortisol stress responsivity in relation to DNA methylation.45
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Furthermore, in addition to baseline GR exon 1F expression data
examined here, GR exon 1F expression data following stress may
provide additional information of its relation with GR-1F methyla-
tion. Finally, we used self-report questionnaires to assess
psychiatric outcomes, constituting a possible source of social
desirability bias, and our questionnaire for exposure to potentially
traumatic events does not take severity and impact into account.
In conclusion, this is the first longitudinal evidence-linking
changes in GR-1F methylation to trauma exposure and the
development of psychopathology symptoms. Our data indicate
that trauma exposure increases GR-1F methylation and that only
increases at specific functionally relevant sites may predispose for
post-deployment psychopathology. These results suggest an
important role for epigenetic regulation of GR functioning after
trauma exposure in the development of psychopathology.
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